Exchange: NASDAQ·Updated 06:59 PM EDT

MRNA News

News
all
press releases
S&P 500, Nasdaq 100, Dow End Week Higher With Traders Eyeing Earnings Season — MSFT, NFLX, SPCX, ASTS In Focus
Wall Street’s biggest banks, including JPMorgan, Morgan Stanley, and Wells Fargo, will report earnings next week.
Stocktwits
S&P 500, Nasdaq 100, Dow End Week Higher With Traders Eyeing Earnings Season — MSFT, NFLX, SPCX, ASTS In Focus
Wall Street’s biggest banks, including JPMorgan, Morgan Stanley, and Wells Fargo, will report earnings next week.
Stocktwits
More News
MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push
Moderna shares on Friday were driven by multiple catalysts, including a Nasdaq-100 entry, a New York Times report on a planned NIH-backed cancer-vaccine push and a price target hike.
Stocktwits
Moderna Stock Hits New 52-Week High: What's Happening?
Moderna shares are rising Friday to a fresh 52-week high. The stock enters the Nasdaq-100 Index. Here's what you should know.read more...
Benzinga
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
MRNA's Nasdaq-100 entry follows a 566% stock surge and stronger cancer therapy prospects, potentially boosting demand from index-tracking funds.
Zacks
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
Key PointsAxsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market...
Nasdaq News: Markets
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.read more...
Benzinga
2026 Brings New Hope in the Fight Against Cancer as Breakthroughs Gather Momentum
NeOnc Technologies (NASDAQ:NTHI), Revolution Medicines (NASDAQ:RVMD), Moderna (NASDAQ:MRNA), Merck (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Genmab (NASDAQ:GMAB), and AbbVie (NYSE:ABBV) are among the companies contributing to a rapidly evolving cancer-treatment landscape in 2026, as researchers pursue new ways to extend survival, target tumors more precisely and give patients additional treatment options.
24-7 Market News
Stocks making the biggest moves midday: Marvell, Moderna, Lamb Weston, Constellation Energy & more
Here are some of the companies making headlines in midday trading...
CNBC: Top News
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?
Merck's 7% dip may offer a buying opportunity as Keytruda drives growth and new products and pipeline assets strengthen its post-2028 outlook.
Zacks
Federal Survey Of 21,990 Kids Ties COVID Shots To Autism, ADHD
Federal Survey Of 21,990 Kids Ties COVID Shots To Autism, ADHD Authored by Steve Watson via Modernity.news, A new analysis of the federal National Health Interview Survey finds children who received a COVID-19 shot had higher odds of autism, ADHD, anxiety, asthma and special-education...
Zero Hedge

Advertisement|Remove ads.